Physician profile
Sopheap Ly
NPI 1780732578
$847.30
in general payments reported to CMS, 2019-2025
12 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.03 · 2022: $14.57 · 2024: $244 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $327.96 | 2024-2025 | |
| Viiv Healthcare Company | $177.45 | 2024-2025 | Apretude, Rukobia |
| Dexcom, INC. | $126.99 | 2024-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $46.85 | 2025 | Aptima |
| Corcept Therapeutics | $34.72 | 2025 | Korlym |
| Abbvie INC. | $31.79 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.77 | 2019 | |
| Glaxosmithkline, LLC. | $18.31 | 2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $17.63 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.57 | 2022 | |
| Lilly USA, LLC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sopheap Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.